机构：[1]Affiliated Hospital Academy of Military Medical Sciences, Digestive Oncology, Beijing, China[2]The First Affiliated Hospital University of Zhejiang, Department of Oncology, Hangzhou, China[3]The Cancer Hospital Medical University of Haerbin, Department of Medical Oncology, Haerbin, China[4]The Cancer Hospital Medical University of Tianjin, Department of Medical Oncology, Tianjin, China[5]The Xuanwu Hospital Capital Medical University, Department of Surgery, Beijing, China首都医科大学宣武医院[6]Academy of Military Medical Sciences, Affiliated Hospital Cancer Center, Beijing, China
第一作者机构：[1]Affiliated Hospital Academy of Military Medical Sciences, Digestive Oncology, Beijing, China
推荐引用方式(GB/T 7714)：
J.M. Xu,F.J. Ge,N. Xu,et al.A randomized phase II study of S-1 monotherapy or S-1 plus leucovorin as 2nd line chemotherapy in patients with advanced pancreatic cancer[J].EUROPEAN JOURNAL OF CANCER.2013,49:S628.
APA：
J.M. Xu,F.J. Ge,N. Xu,Y.X. Bai,Y.Q. Zhang...&Y. Wang.(2013).A randomized phase II study of S-1 monotherapy or S-1 plus leucovorin as 2nd line chemotherapy in patients with advanced pancreatic cancer.EUROPEAN JOURNAL OF CANCER,49,
MLA：
J.M. Xu,et al."A randomized phase II study of S-1 monotherapy or S-1 plus leucovorin as 2nd line chemotherapy in patients with advanced pancreatic cancer".EUROPEAN JOURNAL OF CANCER 49.(2013):S628
医学